Close Menu

NEW YORK – Personalis said today that it will employ its ImmunoID NeXT platform in an ovarian cancer study spearheaded by the University of New Mexico Comprehensive Cancer Center and the New Mexico Alliance for Cancer Care.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.